⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615 | 0.71 | — | — | |
| SCHEMBL124259 | 0.67 | — | — | |
| SCHEMBL596397 | 0.67 | — | — | |
| SCHEMBL7314099 | 0.59 | — | — | |
| SCHEMBL137800 | 0.59 | — | — | |
| SCHEMBL596817 | 0.59 | — | — | |
| SCHEMBL2139113 | 0.58 | — | — | |
| SCHEMBL2916501 | 0.57 | — | — | |
| SCHEMBL27583411 | 0.53 | — | — | |
| SCHEMBL3910040 | 0.53 | TRIM24 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973656-B1 | HETEROGENEOUS CHIRAL CATALYST | AGENCY SCIENCE TECH & RES (SG) | 2012-05-16 | — | — | EP | claimed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | claimed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | claimed |
| US-20090281358-A1 | HETEROGENEOUS CHIRAL CATALYST | AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) | 2009-11-12 | — | — | US | claimed |
| EP-1973656-A4 | HETEROGENEOUS CHIRAL CATALYST | AGENCY SCIENCE TECH & RES (SG) | 2009-08-05 | — | — | EP | claimed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | claimed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | claimed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | claimed |
| EP-1973656-A1 | HETEROGENEOUS CHIRAL CATALYST | Agency for Science, Technology and Research (SG) | 2008-10-01 | — | — | EP | claimed |
| WO-2007084075-A1 | HETEROGENEOUS CHIRAL CATALYST | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-07-26 | — | — | WO | claimed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | claimed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | claimed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | claimed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-4070477-A | PENICILLINS | CIBA-GEIGY CORPORATION (US) | 1978-01-24 | — | — | US | disclosed |
| US-4058521-A | 2-Halomethyl-2-nucleophilic substituted methyl penicillins | SHIONOGI & CO., LTD. (JA) | 1977-11-15 | — | — | US | disclosed |
| US-4013650-A | PROCESS FOR THE MANUFACTURE OF 3-METHYLENE-CEPHAM COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-3989695-A | 7β-Amino-cepham-3-ol-4-carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1976-11-02 | — | — | US | disclosed |